Choosing the net survival method for cancer survival estimation

Eur J Cancer. 2015 Jun;51(9):1123-9. doi: 10.1016/j.ejca.2013.09.019. Epub 2013 Oct 29.

Abstract

Background: A new net survival method has been introduced by Pohar Perme et al. (2012 [4]) and recommended to substitute the relative survival methods in current use for evaluating population-based cancer survival.

Methods: The new method is based on the use of continuous follow-up time, and is unbiased only under non-informative censoring of the observed survival. However, the population-based cancer survival is often evaluated based on annually or monthly tabulated follow-up intervals. An empirical investigation based on data from the Finnish Cancer Registry was made into the practical importance of the censoring and the level of data tabulation. A systematic comparison was made against the earlier recommended Ederer II method of relative survival using the two currently available computer programs (Pohar Perme (2013) [10] and Dickman et al. (2013) [11]).

Results: With exact or monthly tabulated data, the Pohar-Perme and the Ederer II methods give, on average, results that are at five years of follow-up less than 0.5% units and at 10 and 14 years 1-2% units apart from each other. The Pohar-Perme net survival estimator is prone to random variation and may result in biased estimates when exact follow-up times are not available or follow-up is incomplete. With annually tabulated follow-up times, estimates can deviate substantially from those based on more accurate observations, if the actuarial approach is not used.

Conclusion: At 5 years, both the methods perform well. In longer follow-up, the Pohar-Perme estimates should be interpreted with caution using error margins. The actuarial approach should be preferred, if data are annually tabulated.

Keywords: Epidemiologic methods; Models; Neoplasms; Net survival; Prognosis; Relative survival.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colonic Neoplasms / mortality
  • Female
  • Finland / epidemiology
  • Follow-Up Studies
  • Gallbladder Neoplasms / mortality
  • Humans
  • Liver Neoplasms / mortality
  • Male
  • Models, Statistical*
  • Neoplasms / mortality*
  • Registries / statistics & numerical data*
  • Survival Analysis
  • Time Factors